<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00828178</url>
  </required_header>
  <id_info>
    <org_study_id>NA_00023813</org_study_id>
    <nct_id>NCT00828178</nct_id>
  </id_info>
  <brief_title>Efficacy of Fish Oil in Lupus Patients</brief_title>
  <official_title>A Randomized, Double-blind, Placebo-controlled, Clinical Trial of Omega-3-polyunsaturated Fatty Acids in Subjects With SLE.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Michelle Petri M.D.,MPH</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Johns Hopkins University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators hypothesize that low-dose dietary supplementation with omega-3 fish oil
      will improve disease activity and endothelial function in Systemic Lupus Erythematosus (SLE)
      patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients with SLE have a fifty-fold increased risk of myocardial infarction. This risk is not
      totally explained by traditional cardiovascular risk factors. In a previous double-blind
      study of atorvastatin in SLE, there was no reduction in surrogate measures of coronary artery
      disease (coronary calcium, coronary IMT, carotid plaque) and no effect on inflammatory
      markers such as ICAM, VCAM, IL-6 and CRP. We need to find novel approaches to reduce coronary
      artery disease in SLE. In a preliminary study, omega-3 was shown to improve flow mediated
      dilation of the brachial artery, oxidative stress and disease activity in lupus patients. In
      this study we will determine if omega-3 improves brachial artery flow dilation, disease
      activity and other vascular inflammatory markers (IL-6, s-VCAM-1, s-ICAM-1) in SLE, in a
      double-blind placebo-controlled trial.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2009</start_date>
  <completion_date type="Actual">February 2011</completion_date>
  <primary_completion_date type="Actual">February 2011</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Effect on Brachial Artery Flow Dilation by Omega-3 Versus Placebo.</measure>
    <time_frame>12 weeks</time_frame>
    <description>The assessment measured mean brachial artery diameter at pre-treatment(baseline) and post-treatment (after 12 weeks).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Effect of Omega-3 Versus Placebo on Disease Activity in SLE.</measure>
    <time_frame>pre-treatment(baseline) and post-treatment (after 12 weeks)</time_frame>
    <description>The assessment measured change in disease activities using SELENA-SLEDAI (Systemic Lupus Erythematosus Disease Activity Index Selena Modification - range 0-105) and PGA (Physician Global Assessment - range 0-3) comparing pre-treatment(baseline) vs post-treatment (after 12 weeks).
SELENA-SLEDAI - range 0-105, high score indicates high disease activity - weighted sum of sub-scale is used as total score.
PGA - range 0-3, high score indicates high disease activity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect on Markers of Inflammation: ICAM and VCAM by Omega-3 Versus Placebo.</measure>
    <time_frame>pre-treatment(baseline) and post-treatment (after 12 weeks)</time_frame>
    <description>The inflammatory markers (sICAM-1 and sVCAM-1) were assessed and compared before and after treatment. change from baseline were reported.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">106</enrollment>
  <condition>Systemic Lupus Erythematosus</condition>
  <arm_group>
    <arm_group_label>Omega-3</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>3 g of Omega-3 (1.8 g eicosapentaenoic acid, 1.2 g docosahexaenoic acid ethyl esters); flow-mediated dilation of the brachial artery</description>
  </arm_group>
  <arm_group>
    <arm_group_label>corn starch</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>corn starch; flow-mediated dilation of the brachial artery</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Omega-3</intervention_name>
    <description>Omega-3-acid ethyl esters (Lovaza) 3 gram once a day for 12 weeks</description>
    <arm_group_label>Omega-3</arm_group_label>
    <other_name>Lovaza</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>flow-mediated dilation of the brachial artery</intervention_name>
    <description>flow-mediated dilation of the brachial artery measurement at baseline and after 12 weeks</description>
    <arm_group_label>Omega-3</arm_group_label>
    <arm_group_label>corn starch</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>corn starch</intervention_name>
    <description>3 capsules qd for 12weeks</description>
    <arm_group_label>corn starch</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with a clinical diagnosis of SLE are eligible.

          -  Patients must be 18 years of age or older and able to give informed consent.

        Exclusion Criteria:

          -  SLE patients who are allergic to fish oil or any omega 3 product.

          -  Patients who are pregnant or are planning to become pregnant or are nursing.

          -  Omega-3 use within the previous 6 weeks of enrollment.

          -  Use of warfarin or heparin.

          -  Patients who have coronary artery disease.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michelle A Petri, MD, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Johns Hopkins University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Lupus Center, Johns Hopkins University</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Johns Hopkins Lupus Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Manzi S, Meilahn EN, Rairie JE, Conte CG, Medsger TA Jr, Jansen-McWilliams L, D'Agostino RB, Kuller LH. Age-specific incidence rates of myocardial infarction and angina in women with systemic lupus erythematosus: comparison with the Framingham Study. Am J Epidemiol. 1997 Mar 1;145(5):408-15.</citation>
    <PMID>9048514</PMID>
  </results_reference>
  <results_reference>
    <citation>Duffy EM, Meenagh GK, McMillan SA, Strain JJ, Hannigan BM, Bell AL. The clinical effect of dietary supplementation with omega-3 fish oils and/or copper in systemic lupus erythematosus. J Rheumatol. 2004 Aug;31(8):1551-6.</citation>
    <PMID>15290734</PMID>
  </results_reference>
  <verification_date>September 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 22, 2009</study_first_submitted>
  <study_first_submitted_qc>January 22, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 23, 2009</study_first_posted>
  <results_first_submitted>September 17, 2013</results_first_submitted>
  <results_first_submitted_qc>September 28, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">November 18, 2016</results_first_posted>
  <last_update_submitted>September 28, 2016</last_update_submitted>
  <last_update_submitted_qc>September 28, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 18, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Johns Hopkins University</investigator_affiliation>
    <investigator_full_name>Michelle Petri M.D.,MPH</investigator_full_name>
    <investigator_title>Principal investigator</investigator_title>
  </responsible_party>
  <keyword>SLE</keyword>
  <keyword>atherosclerosis</keyword>
  <keyword>omega-3</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lupus Erythematosus, Systemic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>106 patients were consented and 87 were randomized. Patients were part of the Hopkins Lupus Cohort seen quarterly.</recruitment_details>
      <pre_assignment_details>Some of patients were excluded before being randomized for several reasons including &quot;change of mind by patient, became pregnant, diagnosed with breast ca&quot;. Therefore a total of 87 patients started the trial.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Fish Oil</title>
          <description>fish oil 3 g of Omega-3 (1.8 g eicosapentaenoic acid, 1.2 g docosahexaenoic acid ethyl esters) daily</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Placebo (corn starch) once daily</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="42"/>
                <participants group_id="P2" count="45">Eighty seven participants were randomized.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="42"/>
                <participants group_id="P2" count="43">Two patients did not complete the study.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Fish Oil</title>
          <description>3 g of Omega-3 (1.8 g eicosapentaenoic acid, 1.2 g docosahexaenoic acid ethyl esters)</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>corn starch</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="42"/>
            <count group_id="B2" value="45"/>
            <count group_id="B3" value="87"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="42"/>
                    <measurement group_id="B2" value="45"/>
                    <measurement group_id="B3" value="87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="48.9" spread="10.6"/>
                    <measurement group_id="B2" value="45.5" spread="10.8"/>
                    <measurement group_id="B3" value="47.2" spread="10.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="41"/>
                    <measurement group_id="B2" value="39"/>
                    <measurement group_id="B3" value="80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="42"/>
                    <measurement group_id="B2" value="45"/>
                    <measurement group_id="B3" value="87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Effect on Brachial Artery Flow Dilation by Omega-3 Versus Placebo.</title>
        <description>The assessment measured mean brachial artery diameter at pre-treatment(baseline) and post-treatment (after 12 weeks).</description>
        <time_frame>12 weeks</time_frame>
        <population>Patients who successfully completed the trial.</population>
        <group_list>
          <group group_id="O1">
            <title>Omega-3</title>
            <description>3 g of Omega-3 (1.8 g eicosapentaenoic acid, 1.2 g docosahexaenoic acid ethyl esters)</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Corn starch</description>
          </group>
        </group_list>
        <measure>
          <title>Effect on Brachial Artery Flow Dilation by Omega-3 Versus Placebo.</title>
          <description>The assessment measured mean brachial artery diameter at pre-treatment(baseline) and post-treatment (after 12 weeks).</description>
          <population>Patients who successfully completed the trial.</population>
          <units>cm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="43"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Post-treatment baseline diameter</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.32" spread="0.04"/>
                    <measurement group_id="O2" value="0.33" spread="0.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pre-treatment baseline diameter</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.32" spread="0.06"/>
                    <measurement group_id="O2" value="0.33" spread="0.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Statistical analysis system (SAS) software was used (SAS Institute Inc. Cary, North Carolina, SAS 9.2). Baseline demographic and clinical characteristics were summarized using appropriate descriptive statistics and compared across treatment groups using Chi-square. Two-sample t tests were used in the statistical analysis of the FMD outcomes. ANCOVA was used to compare the groups with respect to changes in clinical variables adjusting for baseline values.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.87</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Effect of Omega-3 Versus Placebo on Disease Activity in SLE.</title>
        <description>The assessment measured change in disease activities using SELENA-SLEDAI (Systemic Lupus Erythematosus Disease Activity Index Selena Modification - range 0-105) and PGA (Physician Global Assessment - range 0-3) comparing pre-treatment(baseline) vs post-treatment (after 12 weeks).
SELENA-SLEDAI - range 0-105, high score indicates high disease activity - weighted sum of sub-scale is used as total score.
PGA - range 0-3, high score indicates high disease activity.</description>
        <time_frame>pre-treatment(baseline) and post-treatment (after 12 weeks)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Omega-3</title>
            <description>3 g of Omega-3 (1.8 g eicosapentaenoic acid, 1.2 g docosahexaenoic acid ethyl esters)</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo (cornstarch)</description>
          </group>
        </group_list>
        <measure>
          <title>Effect of Omega-3 Versus Placebo on Disease Activity in SLE.</title>
          <description>The assessment measured change in disease activities using SELENA-SLEDAI (Systemic Lupus Erythematosus Disease Activity Index Selena Modification - range 0-105) and PGA (Physician Global Assessment - range 0-3) comparing pre-treatment(baseline) vs post-treatment (after 12 weeks).
SELENA-SLEDAI - range 0-105, high score indicates high disease activity - weighted sum of sub-scale is used as total score.
PGA - range 0-3, high score indicates high disease activity.</description>
          <units>Units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="43"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>SELENA-SLEDAI</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.5" spread="2"/>
                    <measurement group_id="O2" value="1.5" spread="2.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PGA</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.49" spread="0.52"/>
                    <measurement group_id="O2" value="0.41" spread="0.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1801</p_value>
            <p_value_desc>This Statistical Analysis applies category SELENA-SLEDAI</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Effect on Markers of Inflammation: ICAM and VCAM by Omega-3 Versus Placebo.</title>
        <description>The inflammatory markers (sICAM-1 and sVCAM-1) were assessed and compared before and after treatment. change from baseline were reported.</description>
        <time_frame>pre-treatment(baseline) and post-treatment (after 12 weeks)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Omega-3</title>
            <description>3 g of Omega-3 (1.8 g eicosapentaenoic acid, 1.2 g docosahexaenoic acid ethyl esters)</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Corn Starch</description>
          </group>
        </group_list>
        <measure>
          <title>Effect on Markers of Inflammation: ICAM and VCAM by Omega-3 Versus Placebo.</title>
          <description>The inflammatory markers (sICAM-1 and sVCAM-1) were assessed and compared before and after treatment. change from baseline were reported.</description>
          <units>ng/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="43"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>sICAM-1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.61" spread="40.27"/>
                    <measurement group_id="O2" value="-5.56" spread="48.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>sVCAM-1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-17.52" spread="101.65"/>
                    <measurement group_id="O2" value="26.57" spread="135.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Omega-3</title>
          <description>3 g of Omega-3 (1.8 g eicosapentaenoic acid, 1.2 g docosahexaenoic acid ethyl esters)</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Placebo (cornstarch)</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="43"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="43"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Michelle Petri</name_or_title>
      <organization>Johns Hopkins University School of Medicine</organization>
      <phone>410-955-9114</phone>
      <email>mpetri@jhmi.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

